Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Warsaw – page 125

1 804 clinical trials in Warsaw, Poland across 33 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Warsaw at a glance
1 804
clinical trials
  • Research sites33
Type of trial
Recruitment status
Quick filters

1 804 trials in Warsaw

Open in trial search

Bladder transitional cell carcinoma

Not recruiting

Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Chronic cutaneous lupus erythematosus

Not recruiting

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Psoriatic arthropathy

Not recruiting

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Sun Pharmaceutical Industries Limited

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Hyperlipidaemia

Not recruiting

Study on Lowering Cholesterol with Rosuvastatin or Rosuvastatin/Ezetimibe in Patients at High or Very High Risk of Cardiovascular Disease with High Cholesterol

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ezetimibe
  • Sponsor:KRKA tovarna zdravil d.d. Novo mesto

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Small cell lung cancer limited stage

Not recruiting

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Type IIa hyperlipidaemia

Not recruiting

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Not recruiting

Study of Dazostinag and Pembrolizumab for Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Takeda Development Center Americas Inc.

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S

Non-small cell lung cancer

Not recruiting

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Myelodysplastic syndrome

Not recruiting

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Syros Pharmaceuticals Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Warsaw

What the registry says about research in the country

01 Respiratory Disease Research

Innovative trials focusing on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) prevention in older adults. Studies include evaluation of novel vaccine formulations and immune responses in various age groups.

  • RSV Prevention Studies
  • Influenza Vaccine Research
  • Respiratory Infection Management

Particular emphasis on vaccine development for adults aged 60 and older.

02 Immunology Studies

Comprehensive research on meningococcal vaccines across different age groups, from infants to toddlers. Studies evaluate safety profiles and immune responses to various vaccine formulations.

  • Pediatric Vaccine Development
  • Immunogenicity Assessment
  • Vaccine Safety Monitoring

Focus on preventive healthcare through advanced vaccination strategies.

03 Dermatology Research

Studies investigating treatments for psoriasis and psoriatic arthritis, including novel biological therapies and their mechanisms of action.

  • Plaque Psoriasis Treatment
  • Biomarker Analysis
  • Combined Therapy Approaches

Emphasis on moderate to severe cases requiring advanced therapeutic interventions.

04 Oncology Studies

Clinical research focusing on bladder cancer and innovative combination therapies. Studies evaluate treatment efficacy in early-stage non-muscle invasive cases.

  • Immunotherapy Research
  • Cancer Treatment Combinations
  • Disease-Free Survival Analysis

Integration of targeted therapies with standard treatments.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.